Phase 3 Schizophrenia Clinical Trials
23 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 23 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia
Schizophrenia
Bristol-Myers Squibb250 enrolled55 locationsNCT06882785
Recruiting
Phase 3
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
Schizophrenia
Central South University400 enrolled8 locationsNCT07045142
Recruiting
Phase 3
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
Schizophrenia
Karuna Therapeutics280 enrolled175 locationsNCT05304767
Recruiting
Phase 3
NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled21 locationsNCT06963034
Recruiting
Phase 3
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia
Cognitive ImpairmentSchizophrenia; Psychosis
European Group for Research In Schizophrenia171 enrolled16 locationsNCT07084831
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Schizophrenia
Bristol-Myers Squibb166 enrolled45 locationsNCT07288567
Recruiting
Phase 3
Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
SchizophreniaBipolar I Disorder
Alkermes, Inc.220 enrolled47 locationsNCT05303064
Recruiting
Phase 3
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Development & Commercialization, Inc.522 enrolled60 locationsNCT06894212
Recruiting
Phase 3
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Treatment-resistant Schizophrenia
Newron Pharmaceuticals SPA400 enrolled5 locationsNCT07184619
Recruiting
Phase 3
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Major Depressive DisorderBipolar DepressionSchizophrenia and Related Disorders
Dr. Inge Winter1,254 enrolled1 locationNCT05603104
Recruiting
Phase 3
A Long-term Administration Trial of SEP-363856 in Patients With Schizophrenia
Schizophrenia
Otsuka Pharmaceutical Co., Ltd.100 enrolled1 locationNCT07225712
Recruiting
Phase 3
Randomized Withdrawal Study in Patients With Schizophrenia
Schizophrenia
Vanda Pharmaceuticals400 enrolled22 locationsNCT06961968
Recruiting
Phase 3
Metformin Treatment on Cognitive Impairment of Schizophrenia
Schizophrenia
Central South University120 enrolled4 locationsNCT05838573
Recruiting
Phase 3
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences800 enrolled24 locationsNCT07114874
Recruiting
Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Schizophrenia
Gedeon Richter Plc.330 enrolled57 locationsNCT03817502
Recruiting
Phase 2Phase 3
MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction
Cognitive ImpairmentMitochondrial AlterationSchizophrenia and Related Disorders
Mclean Hospital100 enrolled3 locationsNCT06191965
Recruiting
Phase 3
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Schizophrenia
Neurocrine Biosciences284 enrolled5 locationsNCT07105098
Recruiting
Phase 3
Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
SchizophreniaAutism Spectrum DisorderBipolar Disorder
Intra-Cellular Therapies, Inc.500 enrolled50 locationsNCT06229210
Recruiting
Phase 3
Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia
Acute Schizophrenia
Otsuka Pharmaceutical Co., Ltd.450 enrolled1 locationNCT05325645
Recruiting
Phase 3
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
Schizophrenia
Reviva Pharmaceuticals690 enrolled18 locationsNCT05184335